About KalVista
KalVista is a publicly listed company based in Cambridge (United States) founded in 2011, and was acquired by Chiesi Pharmaceuticals in April 2026. Therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors. KalVista has raised $13.18 million across 3 funding rounds from investors including Chiesi Pharmaceuticals, RA Capital and Longwood Fund. The company has 270 employees. KalVista offers products and services including Sebetralstat. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity is KalVista Pharmaceuticals. Its competitors include Roivant Sciences, Gilead and Lilly; 1 of its 3 listed competitors has raised funding.
Company details
KalVista therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors through providing healthcare solutions, diversified pharmaceuticals, and drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Cambridge, United States
- Employees 270
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website kalvista.com
- Social LinkedIn X
- Acquired by Chiesi Pharmaceuticals (Apr 2026)
- Legal Name Kalvista Pharmaceuticals, Inc.
- Net Profit-$183.44 M (USD)-44.85as on Apr 30, 2025
- EBITDA-$192.07 M (USD)-29.7as on Apr 30, 2025
- Total Equity Funding$13.18M (USD)
in 3 rounds
- Latest Funding Round$33M (USD), Post-IPO
Jul 2015
- InvestorsChiesi Pharmaceuticals
& 6 more
- Employee Count270
- Acquired byChiesi Pharmaceuticals
(Apr 2026)
Products & Services of KalVista
KalVista offers a comprehensive portfolio of products and services, including Sebetralstat.
Oral inhibitor targeting Factor XIIa for HAE treatment.
Funding Insights of KalVista
KalVista has successfully raised a total of $13.18M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $33 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.18M
- Total Rounds 3
- Last Round Post-IPO — $33M
- First Round $13.18M
(Aug 2011)
- Investors Count 6
All 3 funding rounds of KalVista with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $33M | Post-IPO | – | – | |
| Nov 2012 | $3.84M | Grant | – | – | |
| Aug 2011 | $13.18M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in KalVista
KalVista has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Chiesi Pharmaceuticals, RA Capital and Longwood Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
| innovateuk.gov.uk | ||||
Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas | 1935 | chiesi.com | Parma, Italy |
Investor details for KalVista
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KalVista
97 people are tracked at KalVista (61 in leadership, 4 in board & advisors, 32 in team); the tracked headcount is 270.
| Name | Role | Group |
|---|---|---|
T. Andrew Crockett | CEO | Leadership |
Edward P. Feener | Chief Scientific Officer | Leadership |
Sam O. | Global Head Clinical Safety And Pharmacovigilance | Leadership |
Kara Goldman | Senior Sales Director | Leadership |
Manny Gaspar | Vice President, Sales And Marketing | Leadership |
April Vecchio | Director, Market Access Strategy & Effectiveness | Leadership |
Paul K. Audhya | Chief Medical Officer | Leadership |
Christopher M. Yea | Chief Development Officer | Leadership |
Keith Tennison | Vice President Of Market Access | Leadership |
Gregg Robinson | Vice President - US Marketing | Leadership |
Markus Heckmann | Executive Director, Head Of Global Marketing | Leadership |
Linda Härndahl | Associate Director Project Management | Leadership |
Jt Newton | Senior Director, Commercial Effectiveness & Training | Leadership |
Dave Lauinger | Senior Sales Director - West | Leadership |
Jennifer Richards | Director GXP Quality | Leadership |
Edith Mercenier | EU Commercial Operations Lead, Associate Director | Leadership |
Nicole Sweeny | Chief Commercial Officer | Leadership |
Melinda L. Hurley | Director, Commercial Finance | Leadership |
Allen Clermont | Director, Preclinical Pharmacology | Leadership |
Johannah Sharman | Director | Leadership |
77 more people are available in the full profile.
Complete people profiles for KalVista
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of KalVista
KalVista is a publicly listed company on the NASDAQ with ticker symbol KALV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Apr 2015
- Listed onNASDAQ: KALV
- Listed entityKalVista Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS4834971032
- Share price$26.73 (+0.04% on the day) · 2026-05-11
- Market capitalisation$1.37B
- Volume (last session)2,345,168
- Analyst consensusNeutral
Financials of KalVista
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$183.4M | -$192.1M | |
| 2023 | -$126.6M | -$148.1M | |
| 2022 | -$92.9M | -$110.1M | |
| 2021 | -$82.3M | -$95.9M | |
| 2020 | -$46.2M | -$57.3M |
Detailed financial statements for KalVista
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of KalVista
5 dated milestones of KalVista across 15 years, from founding to its latest funding, stage changes and deals.
- Founded KalVista is founded.
- Funding First funding round of $13.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $33.0M.
- Exit Acquired by Chiesi Pharmaceuticals.
Competitors of KalVista
KalVista has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, Gilead and Lilly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed competitors of KalVista
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of KalVista
The website of KalVista (kalvista.com) receives about 6.6K visits a month and ranks #2,611,883 among all websites worldwide, #3,573 in Biotechnology and Pharmaceuticals.
- Monthly visits6.6K
▼ 18.1% vs previous month
- Unique visitors3.5K
per month
- Global rank#2,611,883
among all websites
- Category rank#3,573
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.9
- Average visit9 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with KalVista. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| joslin.org | 100% | 59.3K | #615,502 | View details | |
google.co.uk | google.co.uk | 65% | #355 | – |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as KalVista (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kalvista
Complete news archive for KalVista
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KalVista
KalVista was founded in 2011.
KalVista is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
KalVista is a funded company, having raised a total of $13.18M across 3 funding rounds to date. The company's 1st funding round was a Series A of $13.18M, raised on Aug 2011.
KalVista has 270 employees.
KalVista therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors through providing healthcare solutions, diversified pharmaceuticals, and drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
KalVista's top competitors include Roivant Sciences, Lilly and Gilead.
KalVista offers Sebetralstat.
Yes, KalVista is publicly traded on NASDAQ under the ticker symbol KALV.
KalVista has 7 investors. Key investors include Chiesi Pharmaceuticals, RA Capital, Longwood Fund, Venrock, and SV Health Investors.
KalVista operates through Kalvista Pharmaceuticals.
Yes. KalVista was acquired by Chiesi Pharmaceuticals in April 2026.